PPA
ACOR

Parametric Portfolio Associates’s Acorda Therapeutics ACOR Stock Holding History

Parametric Portfolio Associates’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-258
Closed -$21K – 4094
2020
Q4 		$21K Hold
258
– – ﹤0.01% 3974
2020
Q3 		$16K Hold
258
– – ﹤0.01% 3911
2020
Q2 		$23K Sell
258
-313
-55% -$33.1K ﹤0.01% 3893
2020
Q1 		$64K Sell
571
-1,788
-76% -$352K ﹤0.01% 3802
2019
Q4 		$577K Buy
2,359
+894
+61% +$226K ﹤0.01% 3311
2019
Q3 		$504K Buy
1,465
+449
+44% +$244K ﹤0.01% 3340
2019
Q2 		$936K Buy
1,016
+27
+3% +$33.2K ﹤0.01% 3082
2019
Q1 		$1.58M Sell
989
-5
-0.5% -$9.01K ﹤0.01% 2785
2018
Q4 		$1.86M Sell
994
-111
-10% -$242K ﹤0.01% 2627
2018
Q3 		$2.6M Buy
1,105
+137
+14% +$424K ﹤0.01% 2530
2018
Q2 		$3.33M Buy
968
+51
+6% +$156K ﹤0.01% 2290
2018
Q1 		$2.6M Buy
917
+19
+2% +$56.9K ﹤0.01% 2429
2017
Q4 		$2.31M Buy
898
+34
+4% +$96.7K ﹤0.01% 2512
2017
Q3 		$2.45M Buy
864
+95
+12% +$250K ﹤0.01% 2447
2017
Q2 		$1.82M Buy
769
+139
+22% +$275K ﹤0.01% 2603
2017
Q1 		$1.59M Buy
630
+205
+48% +$590K ﹤0.01% 2600
2016
Q4 		$958K Buy
425
+5
+1% +$11.9K ﹤0.01% 2855
2016
Q3 		$1.05M Buy
420
+4
+1% +$11.9K ﹤0.01% 2769
2016
Q2 		$1.27M Sell
416
-21
-5% -$68.3K ﹤0.01% 2648
2016
Q1 		$1.39M Buy
437
+2
+0.5% +$8.3K ﹤0.01% 2679
2015
Q4 		$2.24M Buy
435
+67
+18% +$293K ﹤0.01% 2148
2015
Q3 		$1.17M Buy
368
+117
+47% +$454K ﹤0.01% 2222
2015
Q2 		$1M Buy
251
+14
+6% +$54.1K ﹤0.01% 2805
2015
Q1 		$945K Buy
237
+5
+2% +$22.9K ﹤0.01% 2830
2014
Q4 		$1.14M Buy
232
+19
+9% +$81.5K ﹤0.01% 2682
2014
Q3 		$865K Buy
213
+31
+17% +$116K ﹤0.01% 2815
2014
Q2 		$737K Sell
182
-6
-3% -$24.5K ﹤0.01% 2949
2014
Q1 		$857K Buy
188
+18
+11% +$72.8K ﹤0.01% 2792
2013
Q4 		$596K Buy
170
+7
+4% +$27.3K ﹤0.01% 3050
2013
Q3 		$668K Buy
163
+21
+15% +$90.5K ﹤0.01% 2896
2013
Q2 		$561K Buy
+142
New +$585K ﹤0.01% 2877

Other funds holding ACOR

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
CCA
Canyon Capital Advisors Dallas, Texas $772M AUM 32.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Parametric Portfolio Associates's ACOR Position: Q1 2021 in Review

Parametric Portfolio Associates sold out of Acorda Therapeutics (ACOR) in Q1 2021, closing a stake of 258 shares — an estimated $21K sold.

Parametric Portfolio Associates first reported a position in ACOR in Q2 2013 and held it in 31 quarters. The position peaked at $3.33M in Q2 2018. 32 funds tracked by Wall St. Rank hold ACOR as of Q1 2021.

  • Parametric Portfolio Associates reported no remaining Acorda Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Parametric Portfolio Associates sold 258 Acorda Therapeutics shares in Q1 2021, an estimated $21K.
  • Parametric Portfolio Associates first reported a position in Acorda Therapeutics in Q2 2013 and held it in 31 quarters.
  • Parametric Portfolio Associates's Acorda Therapeutics position peaked at $3.33M in Q2 2018.
  • 32 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2021.

Based on Parametric Portfolio Associates's 13F filing for Q1 2021, filed 17 May 2021.